Camurus AB stock fell 6.4% to 507.5 SEK after the U.S. Food and Drug Administration issued a new Complete Response Letter on the PDUFA action date for Oclaiz (CAM2029), the company’s once-monthly subcutaneous octreotide injection for acromegaly. The setback arrived exactly on the day regulators were required to act, prompting a sharp intraday move that saw shares trade as low as 499.8 SEK.
The FDA did not point to any deficiencies in Oclaiz’s clinical efficacy or safety profile. Instead, the agency highlighted unresolved manufacturing observations at a third-party production site and requested a minor labeling adjustment. Those issues were the explicit grounds for the regulator’s response.
Analysts at Jefferies quickly translated the regulatory response into a revised timeline for U.S. approval. The firm’s base case assumes Camurus will resubmit its application in the fourth quarter of 2026, contingent on validating a second contract manufacturer and completing a reinspection. With that sequence, Jefferies now views a U.S. approval as most likely to occur in the first half of 2027.
Jefferies also quantified the potential market reaction, warning that the stock could decline by the high-teens to low-twenties percent range following the news. That guidance aligns with the session’s intra-day losses, which pushed the shares further from their 52-week high and closer to the 52-week low.
The timing of the regulatory letter coincided with a broader market pullback. Global equities were under material pressure, with major U.S. indices falling sharply, creating a risk-off backdrop that amplified selling in growth-oriented pharmaceutical and biotech names. Swedish biotech peers traded lower as well, reflecting sector-wide caution.
Collectively, a visible regulatory reversal on a high-profile PDUFA date, a meaningful delay to the anticipated U.S. revenue ramp for Oclaiz, and a weakening macro environment drove CAMX shares below the mid-point of their 52-week trading range. The stock now sits nearer to its 52-week low of 430.8 SEK than to its 52-week high of 754.5 SEK.
Clear summary
On its PDUFA action date the FDA issued a Complete Response Letter for Oclaiz due to manufacturing observations at a third-party facility and a requested labeling change. There were no cited clinical safety or efficacy concerns. Jefferies expects resubmission in Q4 2026 and potential approval in H1 2027, and warned of a significant share price correction. The wider market downturn intensified the sell-off.